Article (Scientific journals)
Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.
SCHEEN, André
2012In Expert Opinion on Drug Metabolism and Toxicology, 8 (3), p. 383-94
Peer Reviewed verified by ORBi
 

Files


Full Text
2012 saxa met d2.pdf
Author postprint (305.15 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] INTRODUCTION: A metformin plus saxagliptin fixed-dose combination is now proposed to clinicians. Furthermore, saxagliptin's license was recently extended to include diabetic patients with moderate or severe renal impairment (RI). However, metformin is still contraindicated in patients with RI. AREAS COVERED: This review analyses the pro and contra of using a combination of saxagliptin and metformin (separately or as a fixed-dose combination) in type 2 diabetic patients with moderate or severe RI. An extensive literature search of all pharmacokinetic data and efficacy/safety profile of metformin and saxagliptin in subjects with RI was performed. EXPERT OPINION: Since both metformin and saxagliptin are excreted via the kidney, dose adjustment is required in case of moderate-to-severe RI (half dose of saxagliptin). However, major discrepancies exist between guidelines (metformin excluded in case of RI because of the risk of lactic acidosis) and real life (metformin widely prescribed in patients with some degree of RI). Physicians should weigh the benefit/risk ratio carefully before deciding to prescribe or withdraw the combination metformin plus saxagliptin in patients with stable RI. A redefinition of contraindications to metformin will enable more physicians to prescribe within guidelines and to administer saxagliptin combined with metformin in more patients who clearly may benefit from this combination.
Disciplines :
Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition
Author, co-author :
SCHEEN, André  ;  Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Language :
English
Title :
Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.
Publication date :
2012
Journal title :
Expert Opinion on Drug Metabolism and Toxicology
ISSN :
1742-5255
eISSN :
1744-7607
Publisher :
Informa Healthcare, United Kingdom
Volume :
8
Issue :
3
Pages :
383-94
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 02 April 2012

Statistics


Number of views
83 (2 by ULiège)
Number of downloads
1 (1 by ULiège)

Scopus citations®
 
13
Scopus citations®
without self-citations
5
OpenCitations
 
10

Bibliography


Similar publications



Contact ORBi